Dyslipidaemia: KOL Insight - New Study Released

Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology?

PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have relegated them to third-line use. Can they move up the treatment algorithm? If so, how will they compete with other recently-approved, and pipeline drugs?

Find out in FirstWord's new report, KOL Insight: Dyslipidaemia. Request sample pages now.

Covering 9 recently marketed drugs, and 6 currently in clinical trials, the report reveals candid insights about the dyslipidaemia landscape from 12 key opinion leaders (KOLs) in North America and Europe.

You'll learn whether competition from Pfizer's pipeline PCSK9 inhibitor, bococizumab can push down prices, how outcomes trials will influence PCSK9 inhibitor use, and which of the myriad pipeline drugs-mainly gene/antisense therapies and small molecules aimed at niche patient populations-are likely to succeed.

Full Report Details at
- http://www.fastmr.com/prod/1180398_dyslipidaemia_kol_insight.aspx?afid=301

Reasons to Get this Report

Expert insight into the dyslipidaemia treatment landscape

The report covers 9 marketed dyslipidaemia drugs and 6 pipeline therapies currently in Phase III trials:

Recently Marketed Drugs

* Praluent (alirocumab; Regeneron/Sanofi): Are Praluent and Repatha well differentiated? Can one brand gain a competitive advantage?
* Repatha (evolocumab; Amgen): Do KOLs expect cardiovascular outcome studies to clarify Repatha's position in the treatment algorithm?

Statin FDC combinations

* Cholib (simvastatin/fenofibrate; AbbVie): What are the key differences between Cholib's and Liptruzet's target patient populations?
* Liptruzet (atorvastatin/ ezetimibe; Merck & Co.): Do KOLs prefer statin/ezetimibe combinations like Liptruzet or fenofibrate combinations like Cholib?

Omega-3 fish oils

* Vascepa (icosapent ethyl; Amarin): Do minor differences between Vascepa and Epanova translate into clinical benefits for either brand?
* Epanova (omega-3 carboxylic acids; AstraZeneca): What are the key factors limiting prescriptions of branded Omega-3s like Epanova?

Gene therapy/antisense oligonucleotide

* Glybera (alipogene tiparvovec; uniQure): Is Glybera's high cost justified? Do KOLs expect it to come down?
* Kynamro (mipomersen; Sanofi): What factors will determine whether Kynamro reaches the European market?

MTP inhibitors

* Juxtapid/Lojuxta (lomitapide; Aegerion Pharmaceuticals): What key advantage do MTP inhibitors offer over other dyslipidaemia drugs?

Pipeline Drugs

PCSK9 inhibitors

* Bococizumab (Pfizer): How do KOLs expect bococizumab to compete with current PCKS9 inhibitors?

Antisense oligonucleotide

* Volanesorsen (Ionis Pharmaceuticals): Are KOLs more optimistic about volanesorsen than previous antisense treatments?

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Head and Neck Squamous Cell Carcinoma: KOL Insight
- COPD: KOL Insight
- Biosimilars in Oncology: KOL Insight
- Rheumatoid Arthritis: KOL Insight
- Targeted Therapies In Asthma: KOL Insight